This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

SmallCap stocks can often be overlooked by institutional investors, yet they offer outsized return potential for those ...

We thank Robert J van Soest and Roderick C N van den Bergh for their Correspondence about the prevention of severe genitourinary events in the PEACE-1 trial. In our trial, we used objective events (eg ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented encouraging preclinical data for its investigational PROteolysis TArgeting ...

Arvinas PROTAC protein degraders have some potential, with vepdegestrant as its late-stage, most promising asset, partnered with Pfizer. Read more on ARVN here.

During his tenure as CEO, Dr. Houston has been instrumental in Arvinas’ success moving six programs into the clinic, reporting the results of the first positive pivotal Phase 3 trial for a PROTAC, and ...

Arvinas' top executive, John Houston, plans to retire after roughly eight years at the helm of the clinical-stage biotechnology company. Arvinas on Wednesday said Houston, who has been president ...

– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of ...

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements.

NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, ...

Shares of Arvinas, Inc. (ARVN) have gained 13.9% over the past four weeks to close the last trading session at $7.39, but there could still be a solid upside left in the stock if short-term price ...

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or ...